Status:
RECRUITING
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Lead Sponsor:
Glaukos Corporation
Conditions:
Glaucoma
Eligibility:
All Genders
35+ years
Phase:
NA
Brief Summary
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical an...
Eligibility Criteria
Inclusion
- Diagnosis of primary open-angle glaucoma
- Phakic or pseudophakic
- Age 35 years or older
Exclusion
- Traumatic, uveitic, neovascular, angle-closure glaucoma or
- glaucoma associated with vascular disorders
- Active corneal inflammation or edema
- Retinal disorders not associated with glaucoma
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT06057051
Start Date
September 1 2023
End Date
August 1 2027
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glaukos Investigator Site
Cincinnati, Ohio, United States, 45242